MabPlex Congratulates Encure Biopharma with FDA IND Clearance of YH001 for the Treatment of a Broad Range of Cancers

November 13, 2019
MabPlex International Ltd. confirms securing United States Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for Encure Biopharma...
Read More

MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services

October 10, 2019
Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan has...
Read More

MabPlex International Announces Appointment of Dr. Wei Chen (Ph.D) as Chief Executive Officer

August 11, 2019
MabPlex International Ltd (MabPlex) has appointed Wei Chen Ph.D as the company's new Chief Executive Officer (CEO). Dr. Chen, a...
Read More

MabPlex Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration

January 17, 2019
MabPlex International, Ltd, a global Contract Development and Manufacturing Organization (CDMO ) offering services in the development and manufacturing of...
Read More

MabPlex M2 Commercial Manufacturing Facility Opening Ceremony

November 6, 2018
Jianmin Fang, PhD (Chairman of MabPlex International Ltd.) highlighted the development and growth of MabPlex over the past five years...
Read More

MabPlex Announces Xinfang Li as Vice President of Process Development

January 9, 2018
January 09, 2018 07:00 AM Eastern Standard Time FREMONT, Calif. & YANTAI, SHANDONG, China--(BUSINESS WIRE)--MabPlex International, a world class CDMO...
Read More

MabPlex USA, Inc. Announces the Opening of its San Diego, CA based Process Development Center of Excellence

May 5, 2016
(San Diego, California; May 30th, 2018) -  MabPlex USA, a subsidiary of MabPlex International, LTD, is excited to announce the...
Read More


April 2, 2016
CONTRACT MANUFACTURER of antibody-drug conjugates emerges in Chinese beach resort town JEAN-FRANÇOIS TREMBLAY, C&EN HONG KONG WE CAN DO IT...
Read More